martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 3, 2026

AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth

View original at globenewswire.com
AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "AI in Genomics Market, till 2040: Distribution by Type of Component, Type of Technology, Type of Functionality…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The rapid increase in genomic data generated by next-generation sequencing technologies has created a strong demand for AI-based tools capable of managing and analyzing complex datasets

    80% confidence
  • The AI in genomics market will grow at a CAGR of 43.75% during the forecast period till 2040

    80% confidence
  • Machine learning algorithms are enabling faster identification of genetic patterns, disease prediction, and drug target discovery, thereby significantly reducing both cost and time in research and development

    80% confidence
  • The global AI in genomics market size is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040

    80% confidence
  • Drug development has traditionally been a lengthy and costly process, often taking several years and substantial investment, but AI-driven tools now enable rapid analysis of vast biomedical datasets

    80% confidence
  • The AI in genomics market faces several critical challenges including data quality and standardization issues, data privacy and compliance concerns, high computational costs, limited availability of skilled AI professionals, and lack of model interpretability

    80% confidence
  • AI algorithms can predict molecular interactions, optimize lead compounds, and identify potential drug candidates with higher precision

    80% confidence
  • The integration of AI into drug discovery and genomics is reshaping the healthcare landscape, expediting innovation, and advancing the global shift toward precision medicine

    80% confidence
  • The market for AI in genomics is expected to grow significantly due to the massive increase in genomic data from next-generation sequencing technologies, which outpaces traditional analysis methods and requires AI's pattern recognition capabilities

    80% confidence
  • Artificial intelligence is transforming the field of genomics by processing huge datasets from DNA sequencing to reveal insights that conventional techniques overlook

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com